fda compounding semaglutide warning letters october 2025 Why the Issued 30 to Telehealth Sites Marketing Compounded GLP-1s Novo Nordisk Calls for FDA

Xie, M., Wu, J

As an observational study, it also cannot prove that the drugs directly caused alopecia

Additionally, patients who stop taking the medications often regain the weight they lost even with diet and exercise

It is important to note that: Additive or synergistic benefits of this specific combination have not been demonstrated in any controlled setting

Form, dose, and protocol are clinical decisions, and your provider's guidance for your situation takes precedence over any positioning language on a product page

Patients who receive and consistently take the medication report results consistent with clinical trial data: 10 to 15% body weight loss over 6 to 12 months on semaglutide, and up to 20%+ on tirzepatide